X hits on this document

Powerpoint document

Clevidipine Phase III Studies: Perioperative Hypertension - page 10 / 65

193 views

0 shares

0 downloads

0 comments

10 / 65

ESCAPE-1

ESCAPE-2

Clevidipine

n=53(%)

Placebo

N=51(%)

Clevidipine

N=61(%)

Placebo

N=49(%)

Any Common Adverse Event

27 (51%)

21 (41%)

32 (53%)

24 (49%)

Acute Renal Failure

5 (9%)

1 (2%)

----

----

Atrial Fibrillation

----

----

13 (21%)

6 (12%)

Nausea

----

----

13 (21%)

6 (12%)

ESCAPE Results:  Safety

Clevidipine Product Information August 2008; The Medicines Company

Treatment emergent adverse reactions and the category on “any common adverse event” in ESCAPE-1 and ESCAPE-2 where the rate on Cleviprex exceeded the rate on Placebo by at least 5% (common adverse reactions)

Document info
Document views193
Page views193
Page last viewedWed Dec 07 22:16:23 UTC 2016
Pages65
Paragraphs1351
Words4734

Comments